Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries
- PMID: 26748356
- DOI: 10.1016/j.actatropica.2015.12.016
Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries
Abstract
The current treatments for visceral leishmaniasis are old and toxic with limited routes of administration. The emergence of drug-resistant Leishmania threatens the efficacy of the existing reservoir of antileishmanials, leading to an urgent need to develop new treatments. It is particularly important to review and understand how the current treatments act against Leishmania in order to identify valid drug targets or essential pathways for next-generation antileishmanials. It is equally important to adapt newly emerging biotechnologies to facilitate the current research on the development of novel antileishmanials in an efficient fashion. This review covers the basic background of the current visceral leishmaniasis treatments with an emphasis on the modes of action. It briefly discusses the role of the immune system in aiding the chemotherapy of leishmaniasis, describes potential new antileishmanial drug targets and pathways, and introduces recent progress on the utilization of high-throughput phenotypic screening assays to identify novel antileishmanial compounds.
Keywords: Drug discovery; Drug target; Leishmaniasis; Mechanism of Action; Phenotypic assay.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
Molecular targets and pathways for the treatment of visceral leishmaniasis.Drug Discov Today. 2018 Jan;23(1):161-170. doi: 10.1016/j.drudis.2017.09.006. Epub 2017 Sep 14. Drug Discov Today. 2018. PMID: 28919438 Review.
-
Developments in the treatment of visceral leishmaniasis.Expert Opin Emerg Drugs. 2009 Sep;14(3):395-410. doi: 10.1517/14728210903153862. Expert Opin Emerg Drugs. 2009. PMID: 19708817 Review.
-
Walking a tightrope: drug discovery in visceral leishmaniasis.Drug Discov Today. 2019 May;24(5):1209-1216. doi: 10.1016/j.drudis.2019.03.007. Epub 2019 Mar 12. Drug Discov Today. 2019. PMID: 30876846 Review.
-
Assay development in leishmaniasis drug discovery: a comprehensive review.Expert Opin Drug Discov. 2022 Feb;17(2):151-166. doi: 10.1080/17460441.2022.2002843. Epub 2021 Nov 24. Expert Opin Drug Discov. 2022. PMID: 34818139 Review.
-
Current scenario of drug development for leishmaniasis.Indian J Med Res. 2006 Mar;123(3):399-410. Indian J Med Res. 2006. PMID: 16778319 Review.
Cited by
-
Traditional Medicinal Ranunculaceae Species from Romania and Their In Vitro Antioxidant, Antiproliferative, and Antiparasitic Potential.Int J Mol Sci. 2024 Oct 12;25(20):10987. doi: 10.3390/ijms252010987. Int J Mol Sci. 2024. PMID: 39456769 Free PMC article.
-
Identification of Leishmania donovani PEX5-PTS1 Interaction Inhibitors through Fluorescence Polarization-Based High-Throughput Screening.Molecules. 2024 Apr 17;29(8):1835. doi: 10.3390/molecules29081835. Molecules. 2024. PMID: 38675653 Free PMC article.
-
Identification of Novel Flavonoids and Ansa-Macrolides with Activities against Leishmania donovani through Natural Product Library Screening.Pathogens. 2024 Feb 28;13(3):213. doi: 10.3390/pathogens13030213. Pathogens. 2024. PMID: 38535556 Free PMC article.
-
Madurastatins with Imidazolidinone Rings: Natural Products or Side-Reaction Products from Extraction Solvents?Int J Mol Sci. 2023 Dec 25;25(1):301. doi: 10.3390/ijms25010301. Int J Mol Sci. 2023. PMID: 38203471 Free PMC article.
-
Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host.Pathogens. 2023 May 12;12(5):706. doi: 10.3390/pathogens12050706. Pathogens. 2023. PMID: 37242374 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
